Real-world effectiveness of novel hormonal agents and docetaxel in patients with prostate cancer: A head-to-head comparison

被引：0
作者：
Jiao, Yuanshi [1 ,2 ]
Ho, Isaac [3 ]
Li, Tunghiu [2 ]
Na, Rong [4 ]
Wong, Chunka [1 ]
Wang, Jiaqi [2 ]
Siu, Steven Wai Kwan [3 ]
Wei, Yan [5 ,6 ]
Chen, Yingyao [5 ,6 ]
Chan, Esther W. [2 ,7 ]
Li, Xue [1 ,2 ,7 ]
机构：
[1] Univ Hong Kong, Li Ka Shing Fac Med, Sch Clin Med, Dept Med, Hong Kong, Peoples R China
[2] Univ Hong Kong, Li Ka Shing Fac Med, Ctr Safe Medicat Practice & Res, Dept Pharmacol & Pharm, Hong Kong, Peoples R China
[3] Queen Mary Hosp, Dept Clin Oncol, Hong Kong, Peoples R China
[4] Univ Hong Kong, Li Ka Shing Fac Med, Sch Clin Med, Dept Surg, Hong Kong, Peoples R China
[5] Fudan Univ, Sch Publ Hlth, Shanghai 200433, Peoples R China
[6] Fudan Univ, Natl Hlth Commiss Key Lab Hlth Technol Assessment, Shanghai 200433, Peoples R China
[7] Lab Data Discovery Hlth D 2 4H, Hong Kong, Peoples R China
来源：
ISCIENCE | 2025年 / 28卷 / 04期
关键词：
ANDROGEN DEPRIVATION THERAPY; ACETATE PLUS PREDNISONE; PART II TREATMENT; INCREASED SURVIVAL; ENZALUTAMIDE; ABIRATERONE; GUIDELINES; MEN; MANAGEMENT; INHIBITORS;
D O I：
10.1016/j.isci.2025.112249
中图分类号：
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号：
07 ; 0710 ; 09 ;
摘要：
Next-generation hormonal-targeted therapies for advanced prostate cancer are widely used. We aimed to evaluate the effectiveness and health resource utilization (HRU) of novel hormonal agents (NHAs) compared to chemotherapy in a real-world context. After propensity score matching, survival analysis revealed no significant difference in overall survival between the individuals treated with NHAs and those treated with docetaxel (hazard ratio [HR]: 1.00, 95% confidence interval [CI]: 0.89-1.11) in the cohort of 1,056 patients. Similar results were observed for prostate-specific antigen (PSA) progression-free survival (HR: 1.02, 95% CI: 0.91-1.14) and PSA response rate (72% [95% CI: 68-76%] for NHAs vs. 76% [95% CI: 72-80%] for docetaxel, p > 0.05). Additionally, patients treated with NHAs had a significantly lower annual HRU during follow up. These findings indicate comparable effectiveness between NHAs and chemotherapy, with a more favorable HRU profile for NHA-treated patients, suggesting potential cost-effectiveness of NHAs.
引用
收藏
页数：12
相关论文
共 52 条
[1]   Selective blockade of androgenic steroid synthesis by novel lyase inhibitors as a therapeutic strategy for treating metastatic prostate cancer [J].
Attard, G ;
Belldegrun, AS ;
de Bono, JS .
BJU INTERNATIONAL, 2005, 96 (09) :1241-1246
[2]   Cost-effectiveness model of abiraterone plus prednisone, cabazitaxel plus prednisone and enzalutamide for visceral metastatic castration resistant prostate cancer therapy after docetaxel therapy resistance [J].
Barqawi, Yazan K. ;
Borrego, Matthew E. ;
Roberts, Melissa H. ;
Abraham, Ivo .
JOURNAL OF MEDICAL ECONOMICS, 2019, 22 (11) :1202-1209
[3]  
Beer TM, 2014, NEW ENGL J MED, V371, P424, DOI 10.1056/NEJMoa1405095
[4]   Prevention of Dabigatran-Related Gastrointestinal Bleeding With Gastroprotective Agents: A Population-Based Study [J].
Chan, Esther W. ;
Lau, Wallis C. Y. ;
Leung, Wai K. ;
Mok, Michael T. C. ;
He, Ying ;
Tong, Teresa S. M. ;
Wong, Ian C. K. .
GASTROENTEROLOGY, 2015, 149 (03) :586-+
[5]   Patient-reported outcomes following abiraterone acetate plus prednisone added to androgen deprivation therapy in patients with newly diagnosed metastatic castration-naive prostate cancer (LATITUDE): an international, randomised phase 3 trial [J].
Chi, Kim N. ;
Protheroe, Andrew ;
Rodriguez-Antolin, Alfredo ;
Facchini, Gaetano ;
Suttman, Henrik ;
Matsubara, Nobuaki ;
Ye, Zhangqun ;
Keam, Bhumsuk ;
Damiao, Ronaldo ;
Li, Tracy ;
McQuarrie, Kelly ;
Jia, Bin ;
De Porre, Peter ;
Martin, Jsaon ;
Todd, Mary B. ;
Fizazi, Karim .
LANCET ONCOLOGY, 2018, 19 (02) :194-206
[6]   Cost-effectiveness analysis of Abiraterone Acetate versus Docetaxel in the management of metastatic castration-sensitive prostate cancer: Hong Kong's perspective [J].
Chiang, Chi Leung ;
So, Tsz Him ;
Lam, Tai Chung ;
Choi, Horace C. W. .
PROSTATE CANCER AND PROSTATIC DISEASES, 2020, 23 (01) :108-115
[7]  
Cornford P, 2024, EAU-EANM-ESTRO-ESUR-ISUP-SIOG guidelines on prostate cancer 2024
[8]   EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer [J].
Cornford, Philip ;
Bellmunt, Joaquim ;
Bolla, Michel ;
Briers, Erik ;
De Santis, Maria ;
Gross, Tobias ;
Henry, Ann M. ;
Joniau, Steven ;
Lam, Thomas B. ;
Mason, Malcolm D. ;
van der Poel, Henk G. ;
van der Kwast, Theo H. ;
Rouviere, Olivier ;
Wiegel, Thomas ;
Mottet, Nicolas .
EUROPEAN UROLOGY, 2017, 71 (04) :630-642
[9]   Biological Evolution of Castration-resistant Prostate Cancer [J].
Davies, Alastair ;
Conteduca, Vincenza ;
Zoubeidi, Amina ;
Beltran, Himisha .
EUROPEAN UROLOGY FOCUS, 2019, 5 (02) :147-154
[10]   Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer [J].
Davis, Ian D. ;
Martin, Andrew J. ;
Stockler, Martin R. ;
Begbie, Stephen ;
Chi, Kim N. ;
Chowdhury, Simon ;
Coskinas, Xanthi ;
Frydenberg, Mark ;
Hague, Wendy E. ;
Horvath, Lisa G. ;
Joshua, Anthony M. ;
Lawrence, Nicola J. ;
Marx, Gavin ;
McCaffrey, John ;
McDermott, Ray ;
McJannett, Margaret ;
North, Scott A. ;
Parnis, Francis ;
Parulekar, Wendy ;
Pook, David W. ;
Reaume, M. Neil ;
Sandhu, Shahneen K. ;
Tan, Alvin ;
Tan, T. Hsiang ;
Thomson, Alastair ;
Tu, Emily ;
Vera-Badillo, Francisco ;
Williams, Scott G. ;
Yip, Sonia ;
Zhang, Alison Y. ;
Zielinski, Robert R. ;
Sweeney, Christopher J. .
NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (02) :121-131
123456